MedTrace Logo

Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19

NCT04578158 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2021-04-22

No results posted yet for this study

Summary

The purpose of this study is to investigate if Quercetin Phytosome is beneficial for the treatment of COVID-19.

Conditions

Interventions

DRUG

Standard COVID-19 care

Patients will receive standard covid-19 care as per the hospital/physician guidelines

DIETARY_SUPPLEMENT

Quercetin Phytosome

Patients will receive a daily dose of 400 mg of oral Quercetin Phytosome

Sponsors & Collaborators

  • Liaquat University of Medical & Health Sciences

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-29
Primary Completion
2021-03-28
Completion
2021-04-15

Countries

  • Pakistan

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04578158 on ClinicalTrials.gov